Nexnos Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 26-07-2024
- Paid Up Capital ₹ 1.91 Cr
as on 26-07-2024
- Company Age 17 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.25 Cr
as on 26-07-2024
- Revenue 373.12%
(FY 2023)
- Profit 2026.66%
(FY 2023)
- Ebitda -460.60%
(FY 2023)
- Net Worth 46.84%
(FY 2023)
- Total Assets 73.46%
(FY 2023)
About Nexnos Pharma
The Corporate was formerly known as Asnani Brokers Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 1.91 Cr.
The company currently has active open charges totaling ₹2.25 Cr.
Kamal Asnani, Vinod Asnani, Rajesh Peswani, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24100RJ2007PTC024845
- Company No.
024845
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Aug 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Chittorgarh, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Nexnos Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinod Asnani  | Director | 14-Aug-2007 | Current |
| Kamal Asnani | Director | 14-Aug-2007 | Current |
| Rajesh Peswani | Director | 26-Mar-2024 | Current |
| Rameshchandra | Director | Current | |
| Ashish Agrawal | Director | 03-May-2023 | Current |
Financial Performance of Nexnos Pharma.
Nexnos Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 373.12% increase. The company also saw a substantial improvement in profitability, with a 2026.66% increase in profit. The company's net worth Soared by an impressive increase of 46.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nexnos Pharma?
In 2023, Nexnos Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Asnani Stock Broker Private LimitedActive 15 years 7 monthsKamal Asnani and Vinod Asnani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Jun 2024 | ₹2.25 Cr | Open |
How Many Employees Work at Nexnos Pharma?
Unlock and access historical data on people associated with Nexnos Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nexnos Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexnos Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
